<DOC>
	<DOCNO>NCT01838902</DOCNO>
	<brief_summary>In study , investigator interest know low dos Primaquine together dihydroartemisinin-piperaquine produce similar effect clear sexual asexual parasite asymptomatic carrier compare recommend dose primaquine decrease risk haemolysis . Children ( &gt; 1 year ) adult normal Glucose-6-phosphate dehydrogenase enzyme level asexual Plasmodium falciparum parasite day screen invite take part study .</brief_summary>
	<brief_title>Primaquine 's Gametocytocidal Efficacy Malaria Asymptomatic Carriers</brief_title>
	<detailed_description>To date , primaquine ( PQ ) , 8-aminoquinoline , currently register product able clear P. falciparum mature gametocyte . However , use still limit haematological toxicity ( haemolytic anaemia ) , particularly exclusively individual glucose-6-phosphate dehydrogenase deficiency ( G6PDd ) , haemolysis occur single PQ dose . Such effect dose-dependent . Considering current recommend dose establish several decade ago small number experimentally challenge volunteer , may possible obtain effect low dose hence decrease risk haemolysis . The propose study four-arm , open label , randomize , control trial . G6PD-normal asymptomatic P. falciparum infect individual identify population screen randomize receive either complete course dihydroartemisinin-piperaquine ( DHA-PPQ ) alone ( control arm ) complete course DHA-PPQ plus single dose PQ 3 differ dose strength ( intervention arm ) , i.e . 0.75mg/kg , 0.4mg base/kg 0.2mg base/kg . The study plan enroll 1,200 individual asymptomatic malaria infection rainy /transmission season ( June - December ) villages around MRC 's field station Walikunda Basse The Gambia . Asymptomatic parasite carrier identify qualitative ( RDT ) quantitative ( parasites count &gt; 20/µl slide microscopy ) method population screen exercise village invite write informed consent screen confirm eligibility , include test qualitative G6PD enzyme function ( fluorescence spot test ) haemoglobin . If eligible , assign one four study arm use block randomization scheme 1:1:1:1 ratio ensure balance enrollment four group . Enrolled participant receive ACT treatment day 0 , 1 2 . On day 2 , participant allocate PQ arm receive dose primaquine base determine body weight . Each participant involvement consist maximum 11 visit 42 day period initiation treatment . The primary end point prevalence P. falciparum gametocyte carrier day 7 , determine QT-NASBA .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Age ≥1 year Weight &gt; 10 Kg P. falciparum monoinfection , density least 20 parasites/μL Axillary temperature &lt; 37.5ºC Resident study area willingness reside duration study Written inform consent ( plus assent child &gt; 12years age ) G6PD Deficiency Haemoglobin &lt; 8g/dl Known allergy study medication Known Pregnancy breastfeed Clear/documented history antimalarial treatment 2 week contact study team History blood transfusion previous 3 month Any chronic acute condition might interfere study judge research clinician History sickle cell anaemia</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Falciparum</keyword>
	<keyword>Direct membrane feeding</keyword>
	<keyword>QT-NASBA</keyword>
	<keyword>Asexual parasite</keyword>
	<keyword>Asymptomatic carrier</keyword>
	<keyword>Gametocytocidal , Gametocyte</keyword>
	<keyword>Transmission block</keyword>
	<keyword>Sexual stage</keyword>
	<keyword>Primaquine</keyword>
	<keyword>Dihydroartemisinin</keyword>
	<keyword>Piperaquine</keyword>
	<keyword>Gambia</keyword>
	<keyword>Africa</keyword>
</DOC>